Oral ondansetron pharmacokinetics: the effect of chemotherapy

• Published in: Journal of clinical pharmacology Vol. 34; no. 7; p. 767
• Main Authors: Hsyu, P H, Pritchard, J F, Bozigian, H P, Gooding, A E, Griffin, R H, Mitchell, R, Bjurstrom, T, Panella, T L, Huang, A T, Hansen, L A
• Format: Journal Article
• Language: English
• Published: England 01.07.1994
• Subjects: Administration, Oral; Adolescent; Adult; Biological Availability; Cisplatin - pharmacology; Cisplatin - therapeutic use; Female; Fluorouracil - pharmacology; Fluorouracil - therapeutic use; Half-Life; Humans; Infusions, Intravenous; Male; Neoplasms - drug therapy; Neoplasms - metabolism; Ondansetron - administration & dosage; Ondansetron - pharmacokinetics; Tablets
• ISSN: 0091-2700
• DOI: 10.1002/j.1552-4604.1994.tb02038.x

The effect of a typical 5-day chemotherapy treatment with cisplatin (20-40 mg/m2 per day) and 5-fluorouracil (5-FU, 1 gm/m2 per day) on the pharmacokinetics of ondansetron was investigated. Twenty cancer patients received 8 mg of ondansetron in three periods, including an oral tablet on day 1, an intravenous infusion on day 4, and an oral tablet on day 5. Absolute bioavailability after the oral dosing on day 1 was 87.5 +/- 31.3%, and on day 5 was 85.2 +/- 22.1% (P > .05). Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 +/- 275 and 381 +/- 222 ng.hour/mL, 53.3 +/- 26.8 and 43.6 +/- 21.7 ng/mL, 1.9 +/- 1.4 and 2 +/- 1.4 hours, and 5.21 +/- 1.78 and 6.19 +/- 1.99 hours, respectively. These values were not significantly different (P > .05). In summary, this study showed that cisplatin and 5-FU did not significantly alter the pharmacokinetics of oral ondansetron in cancer patients during the 5 days of chemotherapy. Oral bioavailability of ondansetron appeared to be greater in cancer patients than in healthy subjects.